Bing Yao. Viela Bio
June 17, 2019 10:37 AM EDTUpdated 10:56 AM
R&D

As­traZeneca spin­out Viela Bio pock­ets $75M on its way to BLA for au­toim­mune drug

Amber Tong

On the verge of a BLA fil­ing for its lead drug in a pipeline spun out of As­traZeneca, Viela Bio has pushed its ven­ture fund­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

DOGE ter­mi­nates lease on FDA qual­i­ty lab in St. Louis and 29 oth­er sites

Mis­lead­ing ex­hib­it booth pan­el lands NJ drug­mak­er an un­ti­tled let­ter from FDA

Swiss biotech ends Phase 2 study in Alzheimer's short­ly af­ter Lil­ly and Bio­gen did the same

Trump blog: Some drug­mak­ers cite FDA, NIH cuts as risk fac­tors

Chi­na bans im­ports of Il­lu­mi­na's DNA se­quencers fol­low­ing US tar­iffs

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times